The rise of induced pluripotent stem cell (iPSC) technologies has opened new avenues for modeling human biology and probing the mechanisms underlying immune responses. Among the most promising cell types derived from iPSCs are macrophages — versatile, tissue-resident sentinels involved in inflammation, infection, and disease progression. Yet, despite their potential, iPSC-derived macrophages have been notoriously difficult to genetically manipulate and even harder to analyze at the protein level due to their limited numbers and fragile biology.
In Daniel Ebner's lab at the University of Oxford’s Target Discovery Institute, Elena Navarro-Guerrero is pushing the limits of what’s possible with iPSC-derived macrophages. As Head of Functional Genomics, she has helped to engineer these immune cells with remarkable efficiency — but generating edited cells is only half the battle. The harder problem comes next: proving, at the protein level, that those edits actually work.
Traditional protein assays, built for abundant material and forgiving conditions, falter when faced with scarce, fragile samples. Navarro-Guerrero’s work exposes a growing disconnect in cell engineering and shows how next-generation protein analysis is finally beginning to close it and unlock new scientific opportunities.
When genetic engineering outpaces protein analysis
The advent of CRISPR/Cas9 revolutionized functional genomics by enabling targeted gene modification across most cell types, with recent advances extending these capabilities to historically difficult populations such as iPSC-derived macrophages and microglia. Yet the scientific promise of CRISPR hinges on a critical step: verification that an engineered edit produces the intended protein-level change.
This is where many researchers hit a wall. Traditional western blotting — long the standard for protein expression measurement — requires relatively large sample volumes, abundant protein, and hands-on processing steps that introduce variability. For rare or non-proliferating populations, like iPSC-derived immune cells, these requirements can be prohibitive.
“We only had a small number of cells because the cell line does not proliferate,” Navarro-Guerrero explained. “The protein samples I had were small.”
This mismatch between cutting-edge genome engineering and decades-old protein detection tools reflects a broader issue in modern biology. As the field moves toward smaller, more physiologically relevant cell systems — including iPSC-derived models, organoids, and primary immune cells — the analytical infrastructure must evolve accordingly. When protein assays require more material than biology can realistically provide, progress stalls.
The analytical bottleneck in immune cell research
iPSC-derived macrophages and microglia serve as powerful platforms to model innate immunity, test therapeutic targets, and investigate chronic inflammation, neurodegeneration, and cancer. However, these cells come with steep logistical challenges:
- Low proliferation, meaning researchers must work with extremely limited cell numbers.
- High variability, particularly when derived across different donors or differentiation batches.
- Fragile phenotypes, making them susceptible to stress from sample preparation.
For scientists engineering these cells with CRISPR/Cas9 or viral delivery systems, accurate protein-level readouts determine whether an edit succeeded, failed, or introduced unexpected effects. Standard assays often fall short in sensitivity, throughput, and consistency, leading to inconclusive results or the need to redirect scarce cell material into multiple assays.
The scientific cost is high. Without reliable protein validation, genetic manipulations can be misread, discoveries delayed, and promising targets discarded simply because current tools are not able to characterize them properly.
This challenge is increasingly common across modern cell biology. From stem-cell-derived neurons to engineered T cells, researchers are searching for analytical workflows that match the sensitivity, speed, and multiplex ability required for miniature, high-value samples.
Evolving approaches in protein analysis
Navarro-Guerrero’s work reflects a broader shift in the field toward capillary-based automated immunoassay systems. These methods use only trace amounts of protein and minimize variability introduced by manual handling. These newer approaches address three core limitations of traditional Western blotting:
- Sample size requirements: Miniaturized capillary immunoassay platforms can analyze only a few microliters of lysate, reaching picogram-level sensitivity. This makes it feasible to work with non-proliferating or hard-to-isolate cell types without sacrificing experimental controls or replicates.
- Reproducibility and automation: Automation reduces run-to-run variability and eliminates manual transfer, membrane handling, and development steps. For genome-editing experiments — where distinguishing between partial and complete knockout is essential — consistent, reproducible results are critical.
- Multiplex protein detection: Modern systems can interrogate multiple targets from the same precious sample. This is especially valuable for immune-cell studies, where researchers often need to track signaling cascades, surface markers, and gene-editing outcomes in parallel.
These advances support a more systematic approach to studying how immune cells respond to genetic alterations. In Navarro-Guerrero’s case, streamlined protein expression assays enabled her to confirm the loss of three non-essential genes — HPRT1, PPIB, and CDK4 — in iPSC-derived macrophages generated via CRISPR/Cas9 and lentiviral transduction. These knockouts, published in Scientific Reports in 2021, provide a blueprint for exploring gene function in macrophage biology more broadly.
Enabling systematic exploration of immune pathways
With reliable protein-level validation, the scope of immune-cell engineering expands dramatically. Navarro-Guerrero’s work demonstrates how improved protein analysis makes it possible to:
- Investigate macrophage roles in chronic inflammation, neurodegeneration, and tumor progression.
- Evaluate phenotypic outcomes of multigene editing.
- Build more predictive iPSC-derived models for drug screening and therapeutic development
- Explore synthetic biology and therapeutic engineering applications in innate immune cells.
The ability to confirm gene edits with confidence accelerates hypothesis testing and reduces the experimental guesswork that often consumes months of effort.
Protein expression analysis aligned with modern biology
As more laboratories adopt iPSC-derived cells, single-cell systems, and increasingly complex gene-editing strategies, the pressure to modernize protein analysis is intensifying. The field is moving toward tools that are more sensitive, automated, multiplexed, and integrative, capable of bridging protein readouts with genomic and transcriptomic workflows.
The long-standing mismatch between cutting-edge biology and legacy analytical tools is beginning to break down. Navarro-Guerrero’s work offers a concrete example of how researchers are overcoming assay limitations through emerging technologies that better match the realities of modern cell engineering. By closing the gap between genome editing and protein validation, scientists can interrogate immune-cell function with far greater resolution, transforming rare cell populations into powerful systems for discovery.
